Gustav Jörgen Ullenhag

Dr. Gustav Jörgen Ullenhag

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2016 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
EEEmma Eriksson
Emma Eriksson
JWJessica Wenthe
Jessica Wenthe
SISandra Irenaeus
Sandra Irenaeus
ALAngelica Loskog
Angelica Loskog
GUGustav Jörgen Ullenhag
Gustav Jörgen Ullenhag
Cancer immunotherapy can be potentiated by conditioning regimens such as cyclophosphamide, which reduces the level of regulatory T cells (tregs). However, myeloid suppressive cells are still remaining. Accordingly to previous reports, gemcitabine improves immune status of cancer patients. In this study, the role of gemcitabine was further explored to map its immunological target cells and molecules in patients with pancreatic cancer. Patient blood was investigated by flow cytometry and cytokine arrays at different time points during gemcitabine treatment. The patients had elevated myeloid-derived suppressor cells (MDSCs), and Tregs at diagnosis. Myeloid cells were in general decreased by gemcitabine. The granulocytic MDSCs were significantly reduced while monocytic MDSCs were not affected. In vitro, monocytes responding to IL-6 by STAT3 phosphorylation were prevented to respond in gemcitabine medium. However, gemcitabine could not prevent STAT3 phosphorylation in IL-6-treated tumor cell lines. TGFβ-1 was significantly reduced after only one treatment and continued to decrease. At the same time, the effector T cell:Treg ratio was increased and the effector T cells had full proliferative capacity during the gemcitabine cycle. However, after a resting period, the level of suppressor cells and TGFβ-1 had been restored showing the importance of continuous conditioning. Gemcitabine regulates the immune system in patients with pancreatic cancer including MDSCs, Tregs and molecules such as TGFβ-1 but does not hamper the ability of effector lymphocytes to expand to stimuli. Hence, it may be of high interest to use gemcitabine as a conditioning strategy together with immunotherapy.

21 January 2019 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
SISandra M. M. Irenaeus
Sandra M. M. Irenaeus
DNDorte Nielsen
Dorte Nielsen
PEPeter Ellmark
Peter Ellmark
JYJeffrey Yachnin
Jeffrey Yachnin
ADAdnan Deronic
Adnan Deronic
GUGustav Jörgen Ullenhag
Gustav Jörgen Ullenhag

1 September 2021 in European Journal of Cancer
Verified
Journal Article
Open access
AJAnna L.V. Johansson
Anna L.V. Johansson
IFIrma Fredriksson
Irma Fredriksson
LMLene Mellemkjaer
Lene Mellemkjaer
HSHanne Stensheim
Hanne Stensheim
PLPäivi Lähteenmäki
Päivi Lähteenmäki
FLFrida E. Lundberg
Frida E. Lundberg
Pregnancy-associated cancer (PAC) is increasing over time in many countries. We provide a comprehensive, population-based overview of cancer survival in women with PAC across five decades. We performed a nationwide cohort study of 121,382 women diagnosed with cancer at age 15-49 between 1970 and 2018 using birth and cancer registers in Sweden. Pregnancy-associated cancer was defined as diagnosed during pregnancy and within one year of delivery, while non-PAC was outside this window. Cox regression estimated adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) comparing cancer mortality for PAC versus non-PAC. In total, 5079 women had a diagnosis of PAC. Cutaneous malignant melanoma, breast, cervical, thyroid and central nervous system (CNS) were the most common sites of PAC. A higher cancer mortality was observed in PAC versus non-PAC for breast (HR = 1.72, 95% CI 1.54-1.93) and uterine cancer (myometrium/unspecified) (8.62, 2.80-26.53), in which all PAC deaths were uterine sarcomas. Increased mortality was also observed in upper digestive tract cancer diagnosed during pregnancy and colon cancer diagnosed during first year after delivery. Contrary, the HR for CNS tumours was significantly decreased (0.71, 0.55-0.91). Survival after PAC improved for most sites over time, with survival after breast cancer during pregnancy in recent years being similar to that of non-pregnancy associated breast cancer. For the majority of sites, PAC was not associated with poorer prognosis compared to non-PAC, a finding which was stable over time. The main exceptions were breast cancer and rarer cancers, such as uterine sarcoma.

31 March 2016 in British Journal of Cancer
Verified
Journal Article
Open access
ALAngelica Loskog
Angelica Loskog
AMAglaia Maleka
Aglaia Maleka
SMSara Mangsbo
Sara Mangsbo
ESEmma Svensson
Emma Svensson
CLChristina Lundberg
Christina Lundberg
GUGustav Jörgen Ullenhag
Gustav Jörgen Ullenhag
The BJC is owned by Cancer Research UK, a charity dedicated to understanding the causes, prevention and treatment of cancer and to making sure that the best new treatments reach patients in the clinic as quickly as possible. The journal reflects these aims. It was founded more than fifty years ago and, from the start, its far-sighted mission was to encourage communication of the very best cancer research from laboratories and clinics in all countries. The breadth of its coverage, its editorial independence and it consistent high standards, have made BJC one of the world's premier general cancer journals. Its increasing popularity is reflected by a steadily rising impact factor.

20 April 2017 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
ASA. Schiza
A. Schiza
JWJessica Wenthe
Jessica Wenthe
SMS. Mangsbo
S. Mangsbo
EEE. Eriksson
E. Eriksson
ANAnders Nilsson
Anders Nilsson
GUGustav Jörgen Ullenhag
Gustav Jörgen Ullenhag
Background and aims: Malignant melanoma is an aggressive tumor sensitive for immunotherapy such as checkpoint blockade antibodies. Still, most patients with late stage disease do not respond, and the side effects can be severe. Stimulation of the CD40 pathway to initiate anti-tumor immunity is a promising alternative. Herein, we demonstrate immune profiling data from melanoma patients treated with an adenovirus-based CD40 ligand gene therapy (AdCD40L).Methods: Peripheral blood mononuclear cells and plasma were collected from malignant melanoma patients (n = 15) enrolled in a phase I/IIa study investigating intratumoral delivery of AdCD40L with or without low dose cyclophosphamide. Cells were analyzed by flow cytometry while plasma samples were analyzed by a multi-array proteomics.Results: All patients had an increased Teffector/Tregulatory cell ratio post therapy. Simultaneously, the death receptors TNFR1 and TRAIL-R2 were significantly up-regulated post treatment. Stem cell factor (SCF), E-selectin, and CD6 correlated to enhanced overall survival while a high level of granulocytic myeloid-derived suppressor cells (gMDSCs), IL8, IL10, TGFb1, CCL4, PlGF and Fl3t ligand was highest in patients with short survival.Conclusions: AdCD40L intratumoral injection induced desirable systemic immune effects that correlated to prolonged survival. Further studies using CD40 stimulation in malignant melanoma are warranted.Trial registrationThe 002:CD40L trial “Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors” (clinicalTrials.gov identifier: NCT01455259) was registered at September 2011

12 August 2016 in BMC Cancer
Verified
Journal Article
Open access
PDF file
AMA. Maleka
A. Maleka
GÅG. Åström
G. Åström
PBP. Byström
P. Byström
GUGustav Jörgen Ullenhag
Gustav Jörgen Ullenhag
Conjunctival malignant melanoma (CMM) is a rare malignancy and in the advanced setting there is no effective treatment. In contrast, half of cutaneous melanomas have BRAF mutations and treatment with BRAF inhibitors is established for patients with disseminated disease. The most common form of ocular melanoma, uveal melanoma, lacks these mutations, however, their presence has been reported for CMM. We used the BRAF inhibitor vemurafenib to treat a 53 year-old female suffering from a BRAFV600E mutated metastatic CMM. The patient benefited from the treatment, a response was evident within a week and she experienced a progression free survival of four months. To our knowledge, this is the first described case of response to vemurafenib treatment in a patient with ocular melanoma.